Search results
Results from the WOW.Com Content Network
Bladder sphincter dyssynergia (also known as detrusor sphincter dyssynergia (DSD) (the ICS standard terminology agreed 1998) [1] and neurogenic detrusor overactivity (NDO)) is a consequence of a neurological pathology such as spinal injury [2] or multiple sclerosis [3] which disrupts central nervous system regulation of the micturition ...
Neurogenic bladder is common with spinal cord injury and multiple sclerosis. [11] Rates of some type of urinary dysfunction surpass 80% one year after spinal cord injury. [ 7 ] Among patients with multiple sclerosis, 20–25% will develop neurogenic bladder although the type and severity bladder dysfunction is variable.
Overactive bladder (OAB) is a common condition where there is a frequent feeling of needing to urinate to a degree that it negatively affects a person's life. [2] The frequent need to urinate may occur during the day, at night , or both. [ 4 ]
Neurogenic disorders like multiple sclerosis, spina bifida, Parkinson's disease, strokes and spinal cord injury can all interfere with nerve function of the bladder. [20] This can lead to neurogenic bladder dysfunction; Overactive bladder syndrome. However, the etiology behind this is usually different between men and women, as mentioned above.
For example, a patient complaining of urinary urgency (or rushing to the toilet), with increased frequency of urination can have overactive bladder syndrome. The cause of this might be detrusor overactivity, in which the bladder muscle (the detrusor) contracts unexpectedly during bladder filling. Urodynamics can be used to confirm the presence ...
The bladder also contains β 3 adrenergic receptors, and pharmacological agonists of this receptor are used to treat overactive bladder. The mucosa of the urinary bladder may herniate through the detrusor muscle. [6] This is most often an acquired condition due to high pressure in the urinary bladder, damage, or existing connective tissue ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
The efficacy of solifenacin to treat neurogenic detrusor overactivity (NDO) was established in two clinical trials with a total of 95 pediatric NDO participants, ages two to 17 years old. [2] The studies were designed to measure (as a primary efficacy endpoint) the maximum amount of urine the bladder could hold after 24 weeks of treatment. [2]